Stamatakis, E., Ahmadi, M. N., Gill, J. M. R. , Thøgersen-Ntoumani, C., Gibala, M. J., Doherty, A. and Hamer, M. (2022) Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality. Nature Medicine, 28, pp. 2521-2529. (doi: 10.1038/s41591-022-02100-x) (PMID:36482104) (PMCID:PMC9800274)
![]() |
Text
288120.pdf - Published Version Available under License Creative Commons Attribution. 6MB |
Abstract
Wearable devices can capture unexplored movement patterns such as brief bursts of vigorous intermittent lifestyle physical activity (VILPA) that is embedded into everyday life, rather than being done as leisure time exercise. Here, we examined the association of VILPA with all-cause, cardiovascular disease (CVD) and cancer mortality in 25,241 nonexercisers (mean age 61.8 years, 14,178 women/11,063 men) in the UK Biobank. Over an average follow-up of 6.9 years, during which 852 deaths occurred, VILPA was inversely associated with all three of these outcomes in a near-linear fashion. Compared with participants who engaged in no VILPA, participants who engaged in VILPA at the sample median VILPA frequency of 3 length-standardized bouts per day (lasting 1 or 2 min each) showed a 38%–40% reduction in all-cause and cancer mortality risk and a 48%–49% reduction in CVD mortality risk. Moreover, the sample median VILPA duration of 4.4 min per day was associated with a 26%–30% reduction in all-cause and cancer mortality risk and a 32%–34% reduction in CVD mortality risk. We obtained similar results when repeating the above analyses for vigorous physical activity (VPA) in 62,344 UK Biobank participants who exercised (1,552 deaths, 35,290 women/27,054 men). These results indicate that small amounts of vigorous nonexercise physical activity are associated with substantially lower mortality. VILPA in nonexercisers appears to elicit similar effects to VPA in exercisers, suggesting that VILPA may be a suitable physical activity target, especially in people not able or willing to exercise.
Item Type: | Articles |
---|---|
Additional Information: | This research has been conducted using the UK Biobank Resource under Application Number 25813. The authors would like to thank all the participants and professionals contributing to the UK Biobank, and S. Paudel for her assistance with an early short report version of this manuscript. This study was funded by an Australian National Health and Medical Research Council Investigator Grant (APP1194510) and Ideas Grant (APP1180812). A.D. is supported by the Wellcome Trust (223100/Z/21/Z), National Institute for Health Research Oxford Biomedical Research Centre, Novo Nordisk, the British Heart Foundation Centre of Research Excellence (grant number RE/18/3/34214), the Alan Turing Institute and the British Heart Foundation (grant number SP/18/4/33803) and Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Gill, Professor Jason |
Authors: | Stamatakis, E., Ahmadi, M. N., Gill, J. M. R., Thøgersen-Ntoumani, C., Gibala, M. J., Doherty, A., and Hamer, M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | Nature Medicine |
Publisher: | Nature Research |
ISSN: | 1078-8956 |
ISSN (Online): | 1546-170X |
Published Online: | 08 December 2022 |
Copyright Holders: | Copyright © The Author(s) 2022 |
First Published: | First published in Nature Medicine 28:2521-2529 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record